Mottet Christian, Schoepfer Alain M, Juillerat Pascal, Cosnes Jacques, Froehlich Florian, Kessler-Brondolo Vera, Seibold Frank, Rogler Gerhard, Vavricka Stephan R, Michetti Pierre
*Division of Gastroenterology, Hôpital Neuchâtelois, Neuchâtel, Switzerland;†Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland;‡Division of Gastroenterology Clinic for Visceral Surgery and Medicine, Inselspital Bern, Bern, Switzerland;§Division of Gastroenterology and Hepxatology, Saint-Antoine Hospital, Pierre et Marie Curie-Paris 6 University, Paris, France;‖Division of Gastroenterology, University Hospital of Basel, Basel, Switzerland;¶Division of Gastroenterology and Hepatology, Ospedale Regionale di Lugano, Lugano, Switzerland;**Division of Gastroenterology and Hepatology, Lindenhofspital Bern, Bern, Switzerland;††Division of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland;‡‡Division of Gastroenterology and Hepatology, Stadtspital Triemli, Zurich, Switzerland; and§§Crohn and Colitis Centre, Clinique La Source-Beaulieu, Lausanne, Switzerland.
Inflamm Bowel Dis. 2016 Nov;22(11):2733-2747. doi: 10.1097/MIB.0000000000000923.
The relevance of azathioprine and 6-mercaptopurine therapy in inflammatory bowel disease, Crohn's disease, and ulcerative colitis, has been challenged in recent publications. In this article, a panel of experts gives advice, based on the relevant literature, on indications and practical use of azathioprine/6-mercaptopurine, prevention, and management of drug adverse reactions and special situations such as vaccination, pregnancy, and lactation.
硫唑嘌呤和6-巯基嘌呤疗法在炎症性肠病、克罗恩病和溃疡性结肠炎中的相关性在最近的出版物中受到了质疑。在本文中，一组专家根据相关文献，就硫唑嘌呤/6-巯基嘌呤的适应证和实际应用、药物不良反应的预防和管理以及诸如疫苗接种、妊娠和哺乳等特殊情况给出了建议。
